stockrow
Saturday 7 November 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
- Revenue
- +44.9%
- EPS
- +3,333.0%
- Free cash flow
- +106.8%
- Total debt
- +4.07%
Quarter to September 2026, against a year earlier
11.55
1.02
+9.69%
Follow ZVRA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
6.54 | 4.55 | 15.09 | 8.55 |
P/S ratio |
4.65 | 4.45 | 6.23 | 4.41 | |
P/FCF ratio |
0.00 | 43.60 | 10.34 | 7.48 | |
P/Operating CF |
89.85 | 88.63 | 49.81 | 64.86 | |
P/B ratio |
3.20 | 2.65 | 3.90 | 2.73 | |
Price to Tangible BV |
3.45 | 2.79 | 4.09 | 2.85 | |
EV/Sales |
3.80 | 3.63 | 5.34 | 3.76 | |
EV/EBITDA |
0.00 | 8.43 | 9.01 | 6.23 | |
EV/Operating CF |
(252.94) | 34.73 | 21.75 | 14.35 | |
EV/FCF |
(203.63) | 35.51 | 8.86 | 6.38 | |
Quick Ratio |
5.46 | 4.74 | 5.02 | 5.21 | |
Current Ratio |
5.68 | 4.89 | 5.17 | 5.46 | |
Net Debt/EBITDA |
(14.64) | (3.87) | (13.39) | (16.33) | |
Debt/Assets |
21.75% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.40 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.46 | 0.54 | 0.49 | 0.51 | |
Operating CF/Net income |
0.47 | 0.17 | 2.03 | 0.55 | |
Capex/Depreciation |
0.22 | (171.65) | (20.52) | (0.60) | |
Interest Coverage |
4.78 | 30.48 | — | — | |
Research and Development Expense of Revenue |
7.68% | 12.13% | 11.31% | 13.08% | |
Selling, General and Administrative Expense of Revenue |
59.65% | 57.38% | 41.75% | 50.67% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
12.55% | 8.57% | 7.49% | 7.08% | |
Graham Net Nets |
0.19 | 0.29 | 0.20 | 0.23 | |
Graham Number |
9.28 | 12.75 | 8.87 | 10.78 | |
Earnings Yield |
15.29% | 22.00% | 6.62% | 11.70% | |
Free Cash Flow Yield |
(0.40%) | 2.29% | 9.67% | 13.36% | |
Revenue per Share |
0.62 | 0.62 | 0.67 | 0.64 | |
Operating CF per Share |
0.10 | 0.11 | 0.29 | 0.17 | |
Capex per Share |
0.00 | 0.75 | 0.08 | 0.00 | |
Free Cash Flow per Share |
0.10 | 0.86 | 0.37 | 0.17 | |
Cash per Share |
3.45 | 3.43 | 3.75 | 3.29 | |
Shareholders Equity per Share |
2.80 | 3.52 | 3.68 | 4.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.80 | 3.52 | 3.68 | 4.02 | |
Free Cash Flow |
5.41 | 50.08 | 21.77 | 9.81 | |
Working Capital |
183.73 | 182.94 | 202.67 | 184.47 | |
Capital Expenditures |
(0.11) | 43.94 | 4.74 | (0.24) | |
Net Current Asset Value |
92.93 | 157.19 | 166.24 | 151.19 | |
EV/EBIT |
0.00 | 0.00 | 8.82 | 6.19 | |
Capex to Sales |
0.00 | (1.21) | (0.12) | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 10.30 | 7.26 | |
| Other line items | |||||
Average Receivables |
16.88 | 17.36 | 20.38 | 18.39 | |
Average Payables |
18.53 | 14.75 | 14.90 | 12.37 | |
Average Inventory |
1.86 | 2.43 | 1.78 | 2.22 | |
Average Assets |
231.43 | 225.64 | 279.49 | 291.85 | |
Average Common Equity |
97.16 | 123.41 | 167.44 | 186.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026